Research Achievements
Leonurine Sulfate (SCM-198)
Leonurine Sulfate (SCM-198)
- Novel chemical entity with no approved counterparts globally, featuring a new target and mechanism, with dual filings in China and the US
- World’s first: CD36-targeted anti-cardiovascular inflammation first-in-class drug, filling a global therapeutic gap in this target area
- Successfully transferred for RMB 150 million in 2016—one of the few landmark drug translation cases in China
Propargylcysteine (ZYZ-802)
Propargylcysteine (ZYZ-802)
- Cystathionine γ-lyase (CSE) was named one of the Top 10 Global Drug Targets by Science in 2022!
- InnoDrug’s research on this target is at the global forefront with exceptional clinical translation potential
Innovative Targets
HDAC4
Highly acclaimed by academia: recognized as ushering in a new era of vascular inflammation research!
JMJD3
Highly acclaimed by academia: recognized as unveiling the emperor’s new clothes in vascular injury research!
SMYD3
Multiple publications in top-tier academic journals including Aging Cell, Aging, and ATVB!